Mouse phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM |
YLA0711MO-48T |
Shanghai YL Biotech |
48T |
EUR 465 |
Human IgG antibody Laboratories manufactures the igg igm spike reagents distributed by Genprice. The Igg Igm Spike reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike IgM. Other Igg products are available in stock. Specificity: Igg Category: Igm Group: Spike
Human Cytomegalovirus IgG / IgM, Toxoplasma IgG / IgM, Rubella IgG Rapid Test Kit |
Abbexa |
20 tests |
EUR 410.4 |
|
Human IgA, IgG and IgM AssayLite Multiplex Fluorescent Immunoassay Kit |
AssayPro |
96 Well Plate |
EUR 1472.4 |
Rat phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM ELISA Kit |
ChemNorm |
96T |
EUR 590.4 |
Rat phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM ELISA Kit |
ChemNorm |
48T |
EUR 409.2 |
Mouse phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM ELISA Kit |
ChemNorm |
96T |
EUR 586.8 |
Mouse phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM ELISA Kit |
ChemNorm |
48T |
EUR 405.6 |
Mouse Phosphatidylinositol antibody IgG/IgM (PI Ab IgG/IgM) CLIA Kit |
Abbexa |
96 tests |
EUR 990 |
|
Spike information
Spike Glycoprotein Antibody |
20-abx300551 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Mouse Monoclonal Anti-Porcine epidemic diarrhea virus Spike protein S1 (PEDV-S1) IgM, unlabeled |
PEDV13-M |
Alpha Diagnostics |
100 ul |
EUR 578.4 |
SARS (IN3) Spike Peptide |
3225P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) SARS (IN3) Spike peptide |
SARS (IN1) Spike Peptide |
3221P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) SARS (IN1) Spike peptide |
SARS (IN2) Spike Peptide |
3223P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) SARS (IN2) Spike peptide |
SARS-CoV Spike Protein |
abx060655-1mg |
Abbexa |
1 mg |
EUR 2030.4 |
|
SARS-CoV Spike Antibody |
3225-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3225-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3219-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3219-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3223-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |